• / Free eNewsletters & Magazine
  • / My Account

CDW

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with ...

    Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C

  2. Morningstar Rating for Stocks Performance Update

    During a recent taping of a business show on which I appear each week, I took some heat for making positive comments about the market?s little slide over the past several weeks. Some folks seemed to think it was odd that I would welcome having more investment opportunities, but I suppose it all ...

  3. “Caution to the Wind”

    Increasing service offerings and acquisitions will help CDW maintain its impressive performance.

  4. Our Take on the First Quarter

    Stocks resumed their rally in 2013 as the continued economic recovery, an accommodative Fed, and the resolution of some fiscal issues buoyed the market.

©2017 Morningstar Advisor. All right reserved.